pTrc99S-ssDsbA-EPA-DNNNS-DQNRT
(Plasmid
#128404)
-
PurposePeriplasmic expression of P. aeruginosa exotoxin A with DNNNS and DQNRT internal glycosylation sites in E. coli
-
Depositing Lab
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 128404 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backbonepTrc99S
- Backbone size w/o insert (bp) 4535
- Total vector size (bp) 6442
-
Vector typeBacterial Expression
Growth in Bacteria
-
Bacterial Resistance(s)Spectinomycin and Streptomycin, 50 & 50 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)DH5alpha
-
Copy numberLow Copy
Gene/Insert
-
Gene/Insert nameExotoxin A
-
SpeciesP. aeruginosa
-
Insert Size (bp)1906
-
Mutation242DNNNS246 and 384DQNRT388 engineered glycosylation sites
-
Entrez GenetoxA (a.k.a. PA1148)
- Promoter trc
-
Tags
/ Fusion Proteins
- 6xHis tag (C terminal on insert)
- DsbA signal sequence for periplasmic translocation (N terminal on backbone)
Cloning Information
- Cloning method Gibson Cloning
- 5′ sequencing primer GACAATTAATCATCCGGCTCG
- 3′ sequencing primer GATTTAATCTGTATCAGG (Common Sequencing Primers)
Resource Information
-
Supplemental Documents
-
A portion of this plasmid was derived from a plasmid made byExotoxin A with internal DNNNS and DQNRT glycosylation sites was originally described by Cuccui, et al. doi.org/10.1098/rsob.130002
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
pTrc99S-ssDsbA-EPA-DNNNS-DQNRT was a gift from Michael Jewett (Addgene plasmid # 128404 ; http://n2t.net/addgene:128404 ; RRID:Addgene_128404) -
For your References section:
On-demand biomanufacturing of protective conjugate vaccines. Stark JC, Jaroentomeechai T, Moeller TD, Hershewe JM, Warfel KF, Moricz BS, Martini AM, Dubner RS, Hsu KJ, Stevenson TC, Jones BD, DeLisa MP, Jewett MC. Sci Adv. 2021 Feb 3;7(6). pii: 7/6/eabe9444. doi: 10.1126/sciadv.abe9444. Print 2021 Feb. 10.1126/sciadv.abe9444 PubMed 33536221